QCG
XENE icon

Quadrant Capital Group’s Xenon Pharmaceuticals XENE Stock Holding History

Quadrant Capital Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-66
Closed -$2.59K – 2848
2024
Q4 		$2.59K Buy
+66
New +$2.73K ﹤0.01% 2462

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Quadrant Capital Group's XENE Position: Q1 2025 in Review

Quadrant Capital Group sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 66 shares — an estimated $2.59K sold.

Quadrant Capital Group first reported a position in XENE in Q4 2024 and held it in 1 quarter. The position peaked at $2.59K in Q4 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Quadrant Capital Group reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 66 Xenon Pharmaceuticals shares in Q1 2025, an estimated $2.59K.
  • Quadrant Capital Group first reported a position in Xenon Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Quadrant Capital Group's Xenon Pharmaceuticals position peaked at $2.59K in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Quadrant Capital Group's 13F filing for Q1 2025, filed 13 May 2025.